A Baylor study compared 25 algorithms in terms of their ability to characterize missense variants and found significant disagreement in their predictions.
CEO Anders Rylander said the company will initially market its DiviTum assay for breast cancer cases, though it could be used to monitor cell proliferation in all cancer types.
A new consensus report suggests RB1 testing and genetic counseling to stratify risk and guide ophthalmic screening in kids with affected family members.
